AstraZeneca (LON:AZN) Given Buy Rating at Shore Capital

AstraZeneca (LON:AZN)‘s stock had its “buy” rating reaffirmed by Shore Capital in a research report issued to clients and investors on Wednesday, ThisIsMoney.Co.Uk reports.

AZN has been the topic of a number of other research reports. JPMorgan Chase & Co. set a GBX 7,900 ($103.23) price target on AstraZeneca and gave the company a “buy” rating in a research report on Tuesday. Goldman Sachs Group set a GBX 5,500 ($71.87) price target on AstraZeneca and gave the company a “sell” rating in a research report on Tuesday, October 1st. Bank of America reaffirmed a “buy” rating and issued a GBX 8,500 ($111.07) price target on shares of AstraZeneca in a research report on Tuesday, October 8th. Jefferies Financial Group increased their price target on AstraZeneca from GBX 6,550 ($85.59) to GBX 6,700 ($87.55) and gave the company a “hold” rating in a research report on Tuesday, October 15th. Finally, Bryan, Garnier & Co reaffirmed a “neutral” rating on shares of AstraZeneca in a research report on Wednesday, July 3rd. Three analysts have rated the stock with a sell rating, six have assigned a hold rating and nine have issued a buy rating to the stock. AstraZeneca has an average rating of “Hold” and a consensus target price of GBX 7,137.81 ($93.27).

AZN stock opened at GBX 6,803 ($88.89) on Wednesday. The company has a debt-to-equity ratio of 144.48, a current ratio of 0.95 and a quick ratio of 0.74. The firm has a market capitalization of $89.23 billion and a P/E ratio of 39.74. The business’s 50-day moving average is GBX 7,066.01 and its two-hundred day moving average is GBX 6,532.84. AstraZeneca has a 1 year low of GBX 5,312 ($69.41) and a 1 year high of GBX 8,227.88 ($107.51).

About AstraZeneca

AstraZeneca PLC discovers, develops, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, autoimmunity, infection, neuroscience, and gastroenterology worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor, Plendil, Seloken/Toprol-XL, Tenormin, and Zestril for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases.

Featured Story: Margin

Analyst Recommendations for AstraZeneca (LON:AZN)

Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.